Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== Further reading == Jenkins, Tiffany (2011). Contesting Human Remains in Museum Collections: the crisis of cultural authority. New York: Routledge. ISBN 9780415879606. Lohman, Jack; Goodnow, Katherine, eds. (2006). Human Remains & Museum Practice. Paris/London: UNESCO Publishing/Museum of London. ISBN 9789231040214. Graham, Shawn; Huffer, Damian (2020). "Reproducibility, Replicability, and Revisiting the Insta-Dead and the Human Remains Trade". Internet Archaeology (55). doi:10.11141/ia.55.11. The Bonetrade: Studying the online trade in human remains with machine learning and neural networks
== Types of nuclides == Although the words nuclide and isotope are often used interchangeably, being isotopes is actually only one relation between nuclides. The following table names some other relations.
=== Conviction === After seven weeks of evidence the judge instructed the jury, emphasising that circumstantial evidence can be sufficient for a finding of guilt and that if two people take part in a murder the law considers them equally guilty regardless of which did the deed. On 21 and 22 November 1995, the jury returned unanimous guilty verdicts for all ten murders. Terming her crimes "appalling and depraved", Mr Justice Mantell sentenced Rose to life imprisonment, emphasising that she should never be paroled. The Lord Chief Justice later decided that she should spend at least twenty-five years in prison, but in July 1997, Home Secretary Jack Straw subjected Rose to a whole life tariff. This was the second instance of a whole life tariff imposed on a woman in the UK in modern times, the first having been serial killer Myra Hindley in 1990.
=== Detoxification === Quinonoid compounds generate reactive oxygen species (ROS) via redox cycling mechanisms and arylating nucleophiles. NQO1 removes quinone from biological systems through detoxification reaction: NAD(P)H + a quinone → NAD(P)+ + a hydroquinone. This reaction oxidises the substrate without the formation of damaging semiquinone and oxygen free radical species. The localization of NQO1 in epithelial and endothelial tissues of mice, rats and humans indicates their importance in detoxifying agent, since their location facilitates exposure to compounds entering the body.
Sources: en.wikipedia.org
ADP-ribose is an intermediate that is produced during the metabolism of NAD+, mono- or poly-unsaturated proteins, and cyclic-ADP ribose. ADP-ribose is a protein-glycating agent, and excess levels of ADP-ribose in the cell can cause non-enzymatic ADP-ribosylation. Non-enzymatic ADP-ribosylation can inactivate protein targets that contain nucleotide-binding sites when the adenylate moiety of ADP-ribose binds to them, and it can also interfere with metabolic regulation that occurs via enzymatic ADP-ribosylation. For example, actin polymerization is inhibited by non-enzymatic ADP-ribosylation at a Cys residue. Thus, it is believed that ADPRase functions in general as a house-cleaning enzyme to eliminate potentially deleterious ADP-ribose from the cell. In the literature, the detoxifying role of ADPRase is directly supported in E. coli cells. But in mammalian cells, there is only an indirect evidence linking ADPRase to a detoxifying role, and this comes from studies of the very specific rat liver ADPRibase-I by cytotoxic agents.
== Alleged ruthenium-106 leak == In September 2017 an estimated amount of 100 to 300 TBq (0.3 to 1 g) of 106Ru was released in Russia, probably in the Ural region. It was, after ruling out release from a reentering satellite, concluded that the source was either in nuclear fuel cycle facilities or radioactive source production. In France levels up to 0.036mBq/m3 of air were measured. It was estimated that for distances of the order of a few tens of kilometres, contamination levels may have exceeded the limits for non-dairy foodstuffs.
Glaxo Wellcome had licensed the drug from Sankyo Company of Japan and had sold it in Britain from October 1, 1997. On May 17, 1998, a 55-year-old patient named Audrey LaRue Jones died of acute liver failure after taking troglitazone. Importantly, she had been monitored closely by physicians at the National Institutes of Health (NIH) as a participant in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) diabetes prevention study. This called into question the efficacy of the monitoring strategy. The NIH responded on June 4 by dropping troglitazone from the study. Dr. David J. Graham, an FDA epidemiologist charged with evaluating the drug, warned on March 26, 1999, of the dangers of using it and concluded that patient monitoring was not effective in protecting against liver failure. He estimated that the drug could be linked to over 430 liver failures and that patients incurred 1,200 times greater risk of liver failure when taking Rezulin. Dr. Janet B. McGill, an endocrinologist who had assisted in the Warner–Lambert's early clinical testing of Rezulin, wrote in a March 1, 2000, letter to Sen. Edward M. Kennedy (D-Mass.): "I believe that the company... deliberately omitted reports of liver toxicity and misrepresented serious adverse events experienced by patients in their clinical studies." On March 21, 2000, the FDA withdrew the drug from the market. Dr. Robert I. Misbin, an FDA medical officer, wrote in a March 3, 2000, letter to Senator John Ashcroft of strong evidence that Rezulin could not be used safely.
Sources: en.wikipedia.org
The stand-off cost three demonstrators their lives in clashes with the army on the night of 20–21 August before the coup leaders, lacking the broad military backing they needed and rapidly losing the fear that had sustained their authority, lost their nerve; Estonia and Latvia seized the moment to declare independence, and coup leader Boris Pugo took his own life rather than face arrest. Gorbachev formally resumed his powers on returning to Moscow, but by then the substance of power had already passed elsewhere—the Communist Party did not even condemn its own plotters until 21 August, by which point Yeltsin had exploited its paralysis to ban the Party outright within the Russian federation. Yeltsin's courage in personally defending the parliament building may have helped break the putsch but at the cost of Gorbachev's remaining authority.
==== Subsidies for Affordable Care Act ("Obamacare") ==== On January 8, 2026, the House voted 230–196 to extend the higher Biden-era subsidies for another three years. Without this extension, it's estimated that monthly premiums will double for many persons who are signed up for the Affordable Care Act. One House Republican said, "I am voting in favor of this discharge and of this legislation to send it to the Senate, so that the Senate will have the opportunity to put forth a reform package that can pass Congress and become law."
== Organization and leadership == The National Institutes of Health (NIH) is composed of 27 Institutes and Centers, most of which include research programs led by a Scientific Director and conducted by federal researchers and their trainees at one of several NIH campus locations. Collectively, these research programs encompass the Intramural Research Program (IRP). The IRP includes the United States National Library of Medicine, an international resource for researchers, and the NIH Clinical Center, the world's largest clinical research hospital. Intramural researchers are affiliated with individual Laboratories, Branches or Centers, which are typically organized around common thematic research goals and approaches, much like a department or center at an academic institution. Within these larger structures, Principal Investigators run Sections or Units devoted to their independent research goals. Core facilities, supported by staff scientists and clinicians, are among the shared resources available to IRP researchers. Scientific interests are not bound by the organizational structure. There exists a full spectrum of scientific interest groups (called SIGs) that brings researchers from different Institutes and Centers together around common areas of scientific interest where ideas can be shared and collaborations initiated. In addition, institutes come together to work cooperatively on major initiatives focused on unraveling the complexities of disease.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.